Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.
| Revenue (TTM) | $19.46B |
| Gross Profit (TTM) | $9.15B |
| EBITDA | $5.29B |
| Operating Margin | 18.60% |
| Return on Equity | 5.66% |
| Return on Assets | 3.59% |
| Revenue/Share (TTM) | $69.87 |
| Book Value | $90.43 |
| Price-to-Book | 2.36 |
| Price-to-Sales (TTM) | 2.97 |
| EV/Revenue | 3.792 |
| EV/EBITDA | 16.01 |
| Quarterly Earnings Growth (YoY) | 46.90% |
| Quarterly Revenue Growth (YoY) | -10.50% |
| Shares Outstanding | $272.39M |
| Float | $272.23M |
| % Insiders | 0.43% |
| % Institutions | 99.50% |
Volatility is currently expanding
BDX, COR and UNF recently hiked dividends, offering investors steady income opportunities as market volatility, inflation and economic uncertainty persist.
Becton, Dickinson and Company NYSE: BDX reported higher fiscal fourth-quarter revenue and adjusted earnings as demand for patient monitoring, biologic drug delivery and other products helped offset a difficult comparison for its Alaris infusion platform.
BD stock lost 6.4% in pre-market trading despite Q4 earnings and revenue beat, as its subdued fiscal 2027 revenue growth outlook raises investor concerns.
Although the revenue and EPS for Becton Dickinson (BDX) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Becton Dickinson (BDX) came out with quarterly earnings of $4.15 per share, beating the Zacks Consensus Estimate of $4.06 per share. This compares to earnings of $3.96 per share a year ago.
Q4 revenue of $5.3 billion increased 5.4% as reported, 5.6% FXN Q4 GAAP and adjusted diluted EPS of $2.52 and $4.15, respectively FY26 revenue of $19.5 billion increased 4.9% as reported, 3.9% FXN FY26 GAAP and adjusted diluted EPS of $5.06 and $12.70, respectively FY26 cash from continuing operations increased 30.0% to $3.6 billion and free cash flow increased 42.5% to $2.9 billion Company issues FY27 guidance FRANKLIN LAKES, N.J., Nov. 5, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2026 fourth quarter and full year, which ended September 30, 2026.
FRANKLIN LAKES, N.J., Nov. 5, 2026 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, has declared a quarterly dividend of $1.06 per common share, an increase of 1.0% from the previous quarter.
FRANKLIN LAKES, N.J., Nov. 4, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Bridget Bagnato has been appointed worldwide president of its Peripheral Intervention business unit, effective November 16.
BD heads into Q4 earnings with expectations of higher profits despite lower revenues, backed by strength in Interventional, Medical Essentials and Biologics.
Besides Wall Street's top-and-bottom-line estimates for Becton Dickinson (BDX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2026.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BDX and any ticker you trade — then tracks every position and per-strategy win rate.
